Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression

Cell Reports

Volumn 15, Issue 1, 2016, Pages 171-180

  Katlinskaya, Yuliya V ^a   Katlinski, Kanstantsin V ^a   Yu, Qiujing ^a   Ortiz, Angelica ^a   Beiting, Daniel P ^a   Brice, Angela ^a   Davar, Diwakar ^b   Sanders, Cindy ^b   Kirkwood, John M ^b   Rui, Hallgeir ^c   Xu, Xiaowei ^d   Koumenis, Constantinos ^e   Diehl, J Alan ^f   Fuchs, Serge Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

BRAF; Interferon receptor; Melanoma; Metastasis; Senescence; Type I interferon

Indexed keywords

AFIMOXIFENE; B RAF KINASE; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HETEROCHROMATIN PROTEIN 1; INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; VEMURAFENIB; ALPHA BETA INTERFERON RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DYSPLASTIC NEVUS; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOCYTE; MELANOMA; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN DEFECT; STROMA CELL; TUMOR VOLUME; UBIQUITINATION; UPREGULATION; ADULT; AGED; ANIMAL; C57BL MOUSE; FEMALE; GENETICS; HEK293 CELL LINE; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL AGING; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HEK293 CELLS; HUMANS; INTERFERON TYPE I; MALE; MELANOCYTES; MELANOMA; MICE; MICE, INBRED C57BL; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION;

EID: 84963545903     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.03.006     Document Type: Article

References (56)

1. Bald T., Landsberg J., Lopez-Ramos D., Renn M., Glodde N., Jansen P., Gaffal E., Steitz J., Tolba R., Kalinke U., et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014, 4:674-687.
2. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
3. Bhattacharya S., HuangFu W.C., Liu J., Veeranki S., Baker D.P., Koumenis C., Diehl J.A., Fuchs S.Y. Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J. Biol. Chem. 2010, 285:2318-2325.
4. Bhattacharya S., Qian J., Tzimas C., Baker D.P., Koumenis C., Diehl J.A., Fuchs S.Y. Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J. Biol. Chem. 2011, 286:22069-22076.
5. Bhattacharya S., HuangFu W.C., Dong G., Qian J., Baker D.P., Karar J., Koumenis C., Diehl J.A., Fuchs S.Y. Anti-tumorigenic effects of type 1 interferon are subdued by integrated stress responses. Oncogene 2013, 32:4214-4221.
6. Bhattacharya S., Katlinski K.V., Reichert M., Takano S., Brice A., Zhao B., Yu Q., Zheng H., Carbone C.J., Katlinskaya Y.V., et al. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol. Med. 2014, 6:384-397.
7. Bonnem E.M., Spiegel R.J. Interferon-alpha: current status and future promise. J. Biol. Response Mod. 1984, 3:580-598.
8. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., Stark G.R. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 2007, 6:975-990.
9. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8:729-740.
10. Critchley-Thorne R.J., Yan N., Nacu S., Weber J., Holmes S.P., Lee P.P. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007, 4:e176.
11. Critchley-Thorne R.J., Simons D.L., Yan N., Miyahira A.K., Dirbas F.M., Johnson D.L., Swetter S.M., Carlson R.W., Fisher G.A., Koong A., et al. Impaired interferon signaling is a common immune defect in human cancer. Proc. Natl. Acad. Sci. USA 2009, 106:9010-9015.
12. Damsky W.E., Curley D.P., Santhanakrishnan M., Rosenbaum L.E., Platt J.T., Gould Rothberg B.E., Taketo M.M., Dankort D., Rimm D.L., McMahon M., Bosenberg M. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011, 20:741-754.
13. Damsky W., Micevic G., Meeth K., Muthusamy V., Curley D.P., Santhanakrishnan M., Erdelyi I., Platt J.T., Huang L., Theodosakis N., et al. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 2015, 27:41-56.
14. Dankort D., Curley D.P., Cartlidge R.A., Nelson B., Karnezis A.N., Damsky W.E., You M.J., DePinho R.A., McMahon M., Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 2009, 41:544-552.
15. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
16. Dong J., Phelps R.G., Qiao R., Yao S., Benard O., Ronai Z., Aaronson S.A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003, 63:3883-3885.
17. Eggermont A.M., Spatz A., Robert C. Cutaneous melanoma. Lancet 2014, 383:816-827.
18. Ferguson B., Soyer H.P., Walker G.J. Clinicopathological characterization of mouse models of melanoma. Methods Mol. Biol. 2015, 1267:251-261.
19. Fisher P.B., Grant S. Effects of interferon on differentiation of normal and tumor cells. Pharmacol. Ther. 1985, 27:143-166.
20. Freund A., Orjalo A.V., Desprez P.Y., Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol. Med. 2010, 16:238-246.
21. Fuchs S.Y. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J. Interferon Cytokine Res. 2013, 33:211-225.
22. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 2011, 208:2005-2016.
23. Gogas H., Kirkwood J.M. Predictors of response to interferon therapy. Curr. Opin. Oncol. 2009, 21:138-143.
24. Hofmann U.B., Westphal J.R., Zendman A.J., Becker J.C., Ruiter D.J., van Muijen G.N. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J. Pathol. 2000, 191:245-256.
25. Hofmann U.B., Eggert A.A., Blass K., Bröcker E.B., Becker J.C. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma. Arch. Dermatol. Res. 2005, 297:154-160.
26. Hou P., Liu D., Dong J., Xing M. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 2012, 11:286-295.
27. Huangfu W.C., Qian J., Liu C., Liu J., Lokshin A.E., Baker D.P., Rui H., Fuchs S.Y. Inflammatory signaling compromises cell responses to interferon alpha. Oncogene 2012, 31:161-172.
28. Kirkwood J.M., Ernstoff M.S. Interferons in the treatment of human cancer. J. Clin. Oncol. 1984, 2:336-352.
29. Kirkwood J.M., Ernstoff M. Melanoma: therapeutic options with recombinant interferons. Semin. Oncol. 1985, 12(Suppl 5):7-12.
30. Kirkwood J.M., Butterfield L.H., Tarhini A.A., Zarour H., Kalinski P., Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J. Clin. 2012, 62:309-335.
31. Kuilman T., Michaloglou C., Mooi W.J., Peeper D.S. The essence of senescence. Genes Dev. 2010, 24:2463-2479.
32. Kumar K.G., Tang W., Ravindranath A.K., Clark W.A., Croze E., Fuchs S.Y. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 2003, 22:5480-5490.
33. Kumar K.G., Krolewski J.J., Fuchs S.Y. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J. Biol. Chem. 2004, 279:46614-46620.
34. Kumar K.G., Barriere H., Carbone C.J., Liu J., Swaminathan G., Xu P., Li Y., Baker D.P., Peng J., Lukacs G.L., Fuchs S.Y. Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J. Cell Biol. 2007, 179:935-950.
35. Kumar K.G., Liu J., Li Y., Yu D., Thomas-Tikhonenko A., Herlyn M., Fuchs S.Y. Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol. Ther. 2007, 6:1437-1441.
36. Liu J., HuangFu W.C., Kumar K.G., Qian J., Casey J.P., Hamanaka R.B., Grigoriadou C., Aldabe R., Diehl J.A., Fuchs S.Y. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe 2009, 5:72-83.
37. Moiseeva O., Mallette F.A., Mukhopadhyay U.K., Moores A., Ferbeyre G. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol. Biol. Cell 2006, 17:1583-1592.
38. Núñez N.G., Andreani V., Crespo M.I., Nocera D.A., Breser M.L., Morón G., Dejager L., Libert C., Rivero V., Maccioni M. IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 2012, 72:592-603.
39. Piehler J., Thomas C., Garcia K.C., Schreiber G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 2012, 250:317-334.
40. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
41. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., et al. High frequency of BRAF mutations in nevi. Nat. Genet. 2003, 33:19-20.
42. Qian J., Zheng H., Huangfu W.C., Liu J., Carbone C.J., Leu N.A., Baker D.P., Fuchs S.Y. Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1. PLoS Pathog. 2011, 7:e1002065.
43. Ramont L., Pasco S., Hornebeck W., Maquart F.X., Monboisse J.C. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. Exp. Cell Res. 2003, 291:1-10.
44. Sikora K. Does interferon cure cancer?. BMJ 1980, 281:855-858.
45. Simons D.L., Lee G., Kirkwood J.M., Lee P.P. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J. Transl. Med. 2011, 9:52.
46. Souroullas G.P., Sharpless N.E. mTOR signaling in melanoma: oncogene-induced pseudo-senescence?. Cancer Cell 2015, 27:3-5.
47. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
48. Tarhini A.A., Gogas H., Kirkwood J.M. IFN-α in the treatment of melanoma. J. Immunol. 2012, 189:3789-3793.
49. Thompson J.F., Scolyer R.A., Kefford R.F. Cutaneous melanoma in the era of molecular profiling. Lancet 2009, 374:362-365.
50. Uzé G., Schreiber G., Piehler J., Pellegrini S. The receptor of the type I interferon family. Curr. Top. Microbiol. Immunol. 2007, 316:71-95.
51. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
52. Yu Q., Katlinskaya Y.V., Carbone C.J., Zhao B., Katlinski K.V., Zheng H., Guha M., Li N., Chen Q., Yang T., et al. DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep. 2015, 11:785-797.
53. Zheng H., Qian J., Carbone C.J., Leu N.A., Baker D.P., Fuchs S.Y. Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood 2011, 118:4003-4006.
54. Zheng H., Qian J., Varghese B., Baker D.P., Fuchs S. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol. Cell. Biol. 2011, 31:710-720.
55. Zingg D., Debbache J., Schaefer S.M., Tuncer E., Frommel S.C., Cheng P., Arenas-Ramirez N., Haeusel J., Zhang Y., Bonalli M., et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun. 2015, 6:6051.
56. Zitvogel L., Galluzzi L., Kepp O., Smyth M.J., Kroemer G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 2015, 15:405-414.